About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

No Longer AvailableNCT03501940

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back. Diagnostic procedures, such as fluorine F 18...

Lead sponsor: Andrei Iagaru•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Andrei Iagaru

PRIMARY OBJECTIVES: I. To evaluate fluorine F 18 DCFPyL (18F-DCFPyL) PET/CT for detection of recurrent prostate cancer after initial therapy in patients with elevated prostate-specific antigen (PSA). OUTLINE: Participants receive fluorine F 18 DCFPyL intravenously (IV). After 60-120 minutes, participants undergo whole body PET/CT. Immediately after the first scan, participants may undergo a second PET/CT without receiving fluorine F 18 DCFPyL. After completion of study, participants are followed up at 24-72 hours.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Biopsy proven prostate adenocarcinoma
•Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy)
•* Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation
•* PSA greater than 0.2 ng/mL measured after at least 6 weeks from radical prostatectomy
•* Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA measurements greater than 0.2 ng/mL)
•* Post-radiation therapy - American Society for Radiation Oncology (ASTRO) - Phoenix consensus definition
•* A rise of PSA measurement of 2 or more ng/mL over the nadir
•Able to provide written consent
•Karnofsky performance status of \> 50 (or Eastern Cooperative Oncology Group \[ECOG\] / World Health Organization \[WHO\] equivalent)

Exclusion Criteria

•Unable to provide informed consent
•Inability to lie still for the entire imaging time
•Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
•Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance

Related studies

The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction

NCT05109208 · Prostate Adenocarcinoma

RECRUITINGPhase 2

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

NCT06499870 · Prostate Adenocarcinoma

RECRUITINGPhase 1/2

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT06616155 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more

RECRUITINGPhase 1

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT07219147 · Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8

RECRUITINGPhase 1

PSMA PET Response Guided SabR in High Risk Pca

NCT06044857 · Prostate Adenocarcinoma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 21, 2022Terms

Trial snapshot

StatusNO_LONGER_AVAILABLE

Phase—

Enrollment—

Start date—

Last updatedJan 21, 2022

Condition

Prostate Adenocarcinoma PSA Level Greater Than 0.2 PSA Level Greater Than or Equal to Two PSA Progression Recurrent Prostate Carcinoma

Locations shown

Stanford Cancer Institute Palo Alto

Palo Alto, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 21, 2022Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions